CGChristiane A. Geluk

Christiane A. Geluk

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Christiane A. Geluk has a total of 35 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • C-reactive protein and angiographic characteristics of stable and unstable coronary artery disease: Data from the prospective PREVEND cohort

    by Christiane A. Geluk, Wendy J. Post, Hans L. Hillege, René A. Tio, Jan G.P. Tijssen, René B. van Dijk, W. Arnold Dijk, Stephan J.L. Bakker, Paul E. de Jong, Wiek H. van Gilst, et al.


  • Open Access

    Measurement of coronary calcium scores by electron beam computed tomography or exercise testing as initial diagnostic tool in low-risk patients with suspected coronary artery disease

    by Christiane A. Geluk, Riksta Dikkers, Patrick J. Perik, René A. Tio, Marco J. W. Götte, Hans L. Hillege, Rozemarijn Vliegenthart, Janneke B. Houwers, Tineke P. Willems, Matthijs Oudkerk, et al.

    We determined the efficiency of a screening protocol based on coronary calcium scores (CCS) compared with exercise testing in patients with suspected coronary artery disease (CAD), a normal ECG and troponin levels. Three-hundred-and-four patients were enrolled in a screening protocol including CCS by electron beam computed tomography (Agatston score), and exercise testing. Decision-making was based on CCS. When CCS≥400, coronary angiography (CAG) was recommended. When CCSP<0.0001). In conclusion, measurement of CCS is an appropriate initial screening test in a well-defined low-risk population with suspected CAD.


  • Open Access

    Measurement of coronary calcium scores or exercise testing as initial screening tool in asymptomatic subjects with ST-T changes on the resting ECG: an evaluation study

    by Christiane A Geluk, Riksta Dikkers, Jan A Kors, René A Tio, Riemer Hja Slart, Rozemarijn Vliegenthart, Hans L Hillege, Tineke P Willems, Paul E de Jong, Wiek H van Gilst, et al.

    Asymptomatic subjects at intermediate coronary risk may need diagnostic testing for risk stratification. Both measurement of coronary calcium scores and exercise testing are well established tests for this purpose. However, it is not clear which test should be preferred as initial diagnostic test. We evaluated the prevalence of documented coronary artery disease (CAD) according to calcium scores and exercise test results. Asymptomatic subjects with ST-T changes on a rest ECG were selected from the population based PREVEND cohort study and underwent measurement of calcium scores by electron beam tomography and exercise testing. With calcium scores ≥10 or a positive exercise test, myocardial perfusion imaging (MPS) or coronary angiography (CAG) was recommended. The primary endpoint was documented obstructive CAD (≥50% stenosis). Of 153 subjects included, 149 subjects completed the study protocol. Calcium scores ≥400, 100–399, 10–99 and <10 were found in 16, 29, 18 and 86 subjects and the primary endpoint was present in 11 (69%), 12 (41%), 0 (0%) and 1 (1%) subjects, respectively. A positive, nondiagnostic and negative exercise test was present in 33, 27 and 89 subjects and the primary endpoint was present in 13 (39%), 5 (19%) and 6 (7%) subjects, respectively. Receiver operator characteristics analysis showed that the area under the curve, as measure of diagnostic yield, of 0.91 (95% CI 0.84–0.97) for calcium scores was superior to 0.74 (95% CI 0.64–0.83) for exercise testing (p = 0.004). Measurement of coronary calcium scores is an appropriate initial non-invasive test in asymptomatic subjects at increased coronary risk.


  • Clinical characteristics, cardiac events and coronary angiographic findings in the prospective PREVEND cohort: an observational study

    by C. A. Geluk, R. A. Tio, J. G. P. Tijssen, R. B. van Dijk, W. A. Dijk, H. L. Hillege, P. E. de Jong, W. H. van Gilst, F. Zijlstra


  • Open Access

    Gatekeeper for coronary angiography

    by Christiane A. Geluk, Felix Zijlstra

    We would like to compliment Hoilund-Carlsen and colleagues on their well-designed study on myocardial perfusion scintigraphy (MPS) as gatekeeper for coronary angiography.1 However, we have some doubts with regard to the use of MPS in a not-low-risk population. In this selection of patients scheduled for coronary angiography, obstructive coronary artery disease (CAD) was present in half of the population. This is more than twice the prevalence found in populations screened for acute chest pain.2 In such not-low-risk populations, it has been advised to use a test with high sensitivity to identify all patients with the most severe forms of disease in order to improve event-free survival and cost-effectiveness at a long term.3 In our opinion, a sensitivity of 81% for obstructive CAD and 94% for three-vessel disease, as was found by Hoilund-Carlsen and colleagues, is too low to incorporate MPS as effective gatekeeper in a pre-coronary angiography strategy.

  • Open Access

    Impact of statins in microalbuminuric subjects with the metabolic syndrome: a substudy of the PREVEND Intervention Trial

    by Christiane A. Geluk, Folkert W. Asselbergs, Hans L. Hillege, Stephan J.L. Bakker, Paul E. de Jong, Felix Zijlstra, Wiek H. van Gilst

    Aims Microalbuminuria frequently clusters with the metabolic syndrome and may identify subjects at increased coronary risk. Statin treatment may reduce the incidence of major adverse cardiac events in subjects with the metabolic syndrome, but evidence is limited. We evaluated the impact of pravastatin treatment on the incidence of major adverse cardiac events in microalbuminuric subjects with the metabolic syndrome. Methods and results This substudy of the PREVEND Intervention Trial (a randomized, placebo-controlled trial with a 2×2 factorial design) included 864 microalbuminuric subjects, who were randomized to fosinopril 20 mg or matching placebo and pravastatin 40 mg or matching placebo (mean follow-up 46 months). The metabolic syndrome was defined according to the NCEP ATPIII-report. Subjects with or without the metabolic syndrome were characterized by a higher age, male sex, and increased albuminuria. The incidence of major adverse cardiac events in subjects with the metabolic syndrome [9.1%; 95% confidence interval (CI) 6.0–13.0%] was increased vs. those without [3.6%; 95% CI 2.3–5.5%; P=0.007). Pravastatin treatment lowered the incidence of major adverse cardiac events in subjects with the metabolic syndrome after adjustment for age and sex (hazard ratio=0.39; 95% CI 0.17–0.89; P=0.025). Conclusion This study supports the use of statins in microalbuminuric subjects with the metabolic syndrome to reduce the incidence of major adverse cardiac events.